𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to: Ranibizumab vs. pegaptanib: a cost-effectiveness study?

✍ Scribed by Luis Javier Hernández-Pastor

Book ID
106098489
Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
47 KB
Volume
248
Category
Article
ISSN
0065-6100

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

DISCOUNTING HEALTH AND COST-EFFECTIVENES
DISCOUNTING HEALTH AND COST-EFFECTIVENESS ANALYSIS: A RESPONSE TO NORD
✍ James K. Hammitt 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

## SUMMARY Nord (2011) criticizes standard arguments which assert that consistency requires that future health benefits must be discounted at the same rate as future costs in cost‐effectiveness analysis (CEA). He suggests these arguments are misguided because they require transitivity of preference